Zimmer Biomet Holdings (NYSE: ZBH) reported Q2 EPS of $1.92, $0.04 better than the analyst estimate of $1.88. Revenue for the quarter came in at $2 billion versus the consensus estimate of $1.99 billion.

Bryan Hanson, President and CEO of Zimmer Biomet, said: "Our achievements during the second quarter, including the improvement of our global Knee and Hip sales performance and ongoing growth within the Asia Pacific region, validate our confidence in our full-year outlook. To continue building on our year-to-date progress, we will remain focused on strategies to support long-term, sustainable revenue growth and value-creation. These priorities include the completion of quality remediation activities, supply recovery efforts, new product introductions and the continuous enhancement of our culture."

For earnings history and earnings-related data on Zimmer Biomet Holdings (ZBH) click here.